Anavex Life Sciences Corp (AVXL) - Net Assets
Based on the latest financial reports, Anavex Life Sciences Corp (AVXL) has net assets worth $112.45 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($120.14 Million) and total liabilities ($7.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Anavex Life Sciences Corp's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $112.45 Million |
| % of Total Assets | 93.6% |
| Annual Growth Rate | 47.89% |
| 5-Year Change | -37.1% |
| 10-Year Change | 1403.91% |
| Growth Volatility | 1805.88 |
Anavex Life Sciences Corp - Net Assets Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Anavex Life Sciences Corp worth.
Annual Net Assets for Anavex Life Sciences Corp (2004–2025)
The table below shows the annual net assets of Anavex Life Sciences Corp from 2004 to 2025. Also explore Anavex Life Sciences Corp annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $94.87 Million | -21.12% |
| 2024-09-30 | $120.26 Million | -15.22% |
| 2023-09-30 | $141.85 Million | -0.45% |
| 2022-09-30 | $142.49 Million | -5.52% |
| 2021-09-30 | $150.82 Million | +453.73% |
| 2020-09-30 | $27.24 Million | +34.24% |
| 2019-09-30 | $20.29 Million | -0.98% |
| 2018-09-30 | $20.49 Million | -15.51% |
| 2017-09-30 | $24.25 Million | +284.49% |
| 2016-09-30 | $6.31 Million | -50.75% |
| 2015-09-30 | $12.81 Million | +6549.68% |
| 2014-09-30 | $192.63K | +107.82% |
| 2013-09-30 | $-2.46 Million | +14.33% |
| 2012-09-30 | $-2.88 Million | -151.68% |
| 2011-09-30 | $-1.14 Million | +61.41% |
| 2010-09-30 | $-2.96 Million | +23.27% |
| 2009-09-30 | $-3.86 Million | -68.30% |
| 2008-09-30 | $-2.29 Million | -395.60% |
| 2007-09-30 | $-462.50K | -2881.78% |
| 2006-09-30 | $-15.51K | +40.39% |
| 2005-09-30 | $-26.02K | -201.62% |
| 2004-09-30 | $25.61K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anavex Life Sciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38243360500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $87.00K | 0.09% |
| Other Components | $477.23 Million | 503.04% |
| Total Equity | $94.87 Million | 100.00% |
Anavex Life Sciences Corp Competitors by Market Cap
The table below lists competitors of Anavex Life Sciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taisun Enterprise Co Ltd
TW:1218
|
$220.63 Million |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
$220.68 Million |
|
El-Mor Electric Installation & Services 1986 Ltd
TA:ELMR
|
$220.78 Million |
|
Netronix
TWO:6143
|
$220.97 Million |
|
APRANGA AB EO 029
F:WHX
|
$220.61 Million |
|
ACP Holdings Acquisition Corp. Class A Ordinary Shares
NASDAQ:ACGC
|
$220.59 Million |
|
KABE Group AB (publ.)
ST:KABE-B
|
$220.57 Million |
|
Sovereign Metals Ltd
AU:SVM
|
$220.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anavex Life Sciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 120,263,000 to 94,869,000, a change of -25,394,000 (-21.1%).
- Net loss of 46,377,000 reduced equity.
- New share issuances of 9,198,000 increased equity.
- Other factors increased equity by 11,785,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.38 Million | -48.89% |
| Share Issuances | $9.20 Million | +9.7% |
| Other Changes | $11.79 Million | +12.42% |
| Total Change | $- | -21.12% |
Book Value vs Market Value Analysis
This analysis compares Anavex Life Sciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 177.75x to 2.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-09-30 | $0.01 | $2.38 | x |
| 2005-09-30 | $-0.01 | $2.38 | x |
| 2006-09-30 | $0.00 | $2.38 | x |
| 2007-09-30 | $-0.10 | $2.38 | x |
| 2008-09-30 | $-0.47 | $2.38 | x |
| 2009-09-30 | $-0.76 | $2.38 | x |
| 2010-09-30 | $-0.55 | $2.38 | x |
| 2011-09-30 | $-0.18 | $2.38 | x |
| 2012-09-30 | $-0.41 | $2.38 | x |
| 2013-09-30 | $-0.31 | $2.38 | x |
| 2014-09-30 | $0.02 | $2.38 | x |
| 2015-09-30 | $0.69 | $2.38 | x |
| 2016-09-30 | $0.18 | $2.38 | x |
| 2017-09-30 | $0.59 | $2.38 | x |
| 2018-09-30 | $0.46 | $2.38 | x |
| 2019-09-30 | $0.41 | $2.38 | x |
| 2020-09-30 | $0.47 | $2.38 | x |
| 2021-09-30 | $2.16 | $2.38 | x |
| 2022-09-30 | $1.85 | $2.38 | x |
| 2023-09-30 | $1.78 | $2.38 | x |
| 2024-09-30 | $1.44 | $2.38 | x |
| 2025-09-30 | $1.11 | $2.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anavex Life Sciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-48.89%) is above the historical average (-310.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -56.22% | 0.00% | 0.00x | 1.10x | $-16.96K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-89.02K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.98K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.53 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.12 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.11 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.49 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.19 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.01 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.45 Million |
| 2014 | -5901.77% | 0.00% | 0.00x | 38.18x | $-11.39 Million |
| 2015 | -94.53% | 0.00% | 0.00x | 1.21x | $-13.39 Million |
| 2016 | -233.61% | 0.00% | 0.00x | 1.51x | $-15.37 Million |
| 2017 | -55.50% | 0.00% | 0.00x | 1.15x | $-15.89 Million |
| 2018 | -85.17% | 0.00% | 0.00x | 1.19x | $-19.50 Million |
| 2019 | -129.60% | 0.00% | -0.03x | 1.25x | $-28.32 Million |
| 2020 | -96.49% | 0.00% | 0.00x | 1.27x | $-29.00 Million |
| 2021 | -25.14% | 0.00% | 0.00x | 1.07x | $-52.99 Million |
| 2022 | -33.67% | 0.00% | 0.00x | 1.07x | $-62.23 Million |
| 2023 | -33.48% | 0.00% | 0.00x | 1.09x | $-61.68 Million |
| 2024 | -35.76% | 0.00% | 0.00x | 1.13x | $-55.03 Million |
| 2025 | -48.89% | 0.00% | 0.00x | 1.09x | $-55.86 Million |
Industry Comparison
This section compares Anavex Life Sciences Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $203,084,613
- Average return on equity (ROE) among peers: -26.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anavex Life Sciences Corp (AVXL) | $112.45 Million | -56.22% | 0.07x | $220.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $110.17 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $308.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $960.81 Million |
| ABVC Biopharma Inc (ABVC) | $30.56K | -78.85% | 1.11x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.95 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $30.68 Million | -84.47% | 0.32x | $3.56 Billion |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more